| Brian S Rafferty, MD | |
|
200 Walnut St, Traer, IA 50675-1142 | |
| (319) 478-8198 | |
| (319) 478-2933 |
| Full Name | Brian S Rafferty |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 34 Years |
| Location | 200 Walnut St, Traer, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881640290 | NPI | - | NPPES |
| 0102434 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 29544 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercyone Waterloo Medical Center | Waterloo, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Covenant Medical Center Inc | 0244148732 | 211 |
News Archive
A new study has confirmed that regular smokers have a significantly increased risk of tooth loss. Male smokers are up to 3.6 times more likely to lose their teeth than non-smokers, whereas female smokers were found to be 2.5 times more likely.
People with a type of arthritis affecting the skin and joints respond significantly better to early, aggressive drug treatment compared to standard care, according to preliminary results presented by a University of Leeds lecturer to a major US conference.
ProteoTech, Inc., a privately held biotechnology company, has entered into a drug development agreement with GlaxoSmithKline (China) R&D Company Limited (GSK) to collaborate on ProteoTech's small molecule technology platform against misfolded proteins to specifically advance work on its alpha-synuclein therapeutic program for the treatment of Parkinson's disease and other synucleinopathies.
Their research, led by Professor Alastair Watson in the University's Faculty of Medicine, could have important implications for the treatment of patients with diseases like Crohn's - an inflammatory bowel disorder that causes severe ulceration in the intestine, leading to pain, bleeding and diarrhoea.
› Verified 9 days ago
| Entity Name | Covenant Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548288160 PECOS PAC ID: 0244148732 Enrollment ID: O20031111000534 |
News Archive
A new study has confirmed that regular smokers have a significantly increased risk of tooth loss. Male smokers are up to 3.6 times more likely to lose their teeth than non-smokers, whereas female smokers were found to be 2.5 times more likely.
People with a type of arthritis affecting the skin and joints respond significantly better to early, aggressive drug treatment compared to standard care, according to preliminary results presented by a University of Leeds lecturer to a major US conference.
ProteoTech, Inc., a privately held biotechnology company, has entered into a drug development agreement with GlaxoSmithKline (China) R&D Company Limited (GSK) to collaborate on ProteoTech's small molecule technology platform against misfolded proteins to specifically advance work on its alpha-synuclein therapeutic program for the treatment of Parkinson's disease and other synucleinopathies.
Their research, led by Professor Alastair Watson in the University's Faculty of Medicine, could have important implications for the treatment of patients with diseases like Crohn's - an inflammatory bowel disorder that causes severe ulceration in the intestine, leading to pain, bleeding and diarrhoea.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brian S Rafferty, MD 2101 Kimball Ave, Ll14, Waterloo, IA 50702-5063 Ph: (319) 272-1590 | Brian S Rafferty, MD 200 Walnut St, Traer, IA 50675-1142 Ph: (319) 478-8198 |
News Archive
A new study has confirmed that regular smokers have a significantly increased risk of tooth loss. Male smokers are up to 3.6 times more likely to lose their teeth than non-smokers, whereas female smokers were found to be 2.5 times more likely.
People with a type of arthritis affecting the skin and joints respond significantly better to early, aggressive drug treatment compared to standard care, according to preliminary results presented by a University of Leeds lecturer to a major US conference.
ProteoTech, Inc., a privately held biotechnology company, has entered into a drug development agreement with GlaxoSmithKline (China) R&D Company Limited (GSK) to collaborate on ProteoTech's small molecule technology platform against misfolded proteins to specifically advance work on its alpha-synuclein therapeutic program for the treatment of Parkinson's disease and other synucleinopathies.
Their research, led by Professor Alastair Watson in the University's Faculty of Medicine, could have important implications for the treatment of patients with diseases like Crohn's - an inflammatory bowel disorder that causes severe ulceration in the intestine, leading to pain, bleeding and diarrhoea.
› Verified 9 days ago
Madison Ann Albert, ARNP Family Medicine Medicare: Medicare Enrolled Practice Location: 200 Walnut St, Traer, IA 50675 Phone: 319-478-8198 | |
Dr. Matthew E Ulven, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 Walnut St, Traer, IA 50675 Phone: 319-272-3020 Fax: 319-478-2933 |